MetaCap

Atossa Therapeutics (ATOS) vs Lipocine (LPCN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lipocine (LPCN) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 53.2% versus a loss of 86.4%. Over five years, LPCN leads with a -92.3% price change compared with -95.3% for ATOS. Lipocine is the larger company by market cap ($16.4 million vs $15.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATOS-86.37%LPCN-53.16%
+273%+85%-104%
Nov 21, 20251 yearNov 20, 2026
ATOS-95.48%LPCN-92.56%
+66%-19%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATOS versus LPCN key metrics
MetricATOSLPCN
Share price$1.60$1.48
Market cap$15.92M$16.39M
1-day change-8.86%-1.33%
YTD return-81.98%-81.57%
1-year return-86.37%-53.16%
5-year return-95.34%-92.30%
EPS (TTM)$-3.92$-1.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.98M
Revenue growth (YoY)—-82.35%
Net income (latest FY)$-34.77M$-9.63M
Operating margin—-524.69%
Net margin—-487.06%
52-week high$14.85$12.37
52-week low$1.59$1.36
Distance from 52-week high-89.26%-88.04%
Analyst consensusstrong_buynone
Avg. price target upside+1091.22%+237.84%
Average volume68.00K1.84M
Shares outstanding9.98M11.07M
Employees1614
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LPCN has outperformed ATOS by 33.2 percentage points over the past year.

About Atossa Therapeutics

ATOS stock →

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

About Lipocine

LPCN stock →

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

ATOS vs LPCN FAQ

Which is bigger, Atossa Therapeutics or Lipocine?

Lipocine (LPCN) is larger, with a market capitalization of $16.39M compared with $15.92M for Atossa Therapeutics (ATOS).

Which stock has performed better over the past year, ATOS or LPCN?

LPCN returned -53.16% over the past 12 months, compared with -86.37% for ATOS (price return, excluding dividends). Past performance does not predict future results.

Are Atossa Therapeutics and Lipocine in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons